证券代码：300049 证券简称：福瑞股份 公告编号：2023-031 内蒙古福瑞医疗科技股份有限公司 关于参加内蒙古辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 为进一步加强与投资者的互动交流，内蒙古福瑞医疗科技股份有限公司（以下简称 "公司"）将参加由内蒙古证监局、内蒙古上市公司协会与深圳市全景网络有限公司联合 举办的"2023 年内蒙古辖区上市公司投资者集体接待日活动"，现将相关事项公告如下： 本 次 活 动 将 采 用 网 络 远 程 的 方 式 举 行 ， 投 资 者 可 登 录 " 全 景 路 演 " 网 站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参与本次 互动交流，活动时间为 2023 年 6 月 9 日（周五）15:30-17:00。届时公司高管等人员将 在线就公司 2022 年度业绩、公司治理、发展战略、经营状况等投资者关心的问题，与 投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 内蒙古福瑞医疗科技股份有限公司董事 ...

Group 1: Financial Performance - The company received a total of 280 million CNY in special government funding, which was distributed in batches over previous years [1] - In 2022, Echosens achieved a revenue of 86.42 million EUR, representing a growth of 21.75% compared to the previous year [2] - As of May 10, 2023, the number of shareholders reached 13,855 [3] Group 2: Product Development and Market Strategy - The company is focusing on the NASH (Non-Alcoholic Steatohepatitis) field, with ongoing clinical trials for multiple NASH drugs [2] - FibroScan, a key product, had over 90% of its sales revenue generated from overseas markets in 2022 [2] - The company launched FibroScan GO in 2022, targeting primary healthcare institutions with a per-use charging model, which is currently being piloted in the US and France [2] Group 3: Research and Development - The company is actively collaborating with major international pharmaceutical companies to support drug clinical trials and provide comprehensive solutions [2] - The current focus in NASH drug development includes companies like Intercept, Madrigal, Pfizer, and others that have reached clinical endpoints [3] - The company is in the early trial phase for its Cordyceps project and cannot yet provide profit contributions [3]

Financial Performance - The company reported total revenue of 611.18 million, with a net profit of 103.44 million, reflecting a profit margin of approximately 16.9%[11]. - The company reported a total revenue of 2.48619 million yuan for the year, with expenses related to employee stock options included in management and sales expenses[50]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a year-over-year growth of 20%[63]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25%[63]. - The company’s operating revenue for 2022 was ¥1,008,765,862.03, representing a 12.27% increase from ¥898,483,228.69 in 2021[198]. - Net profit attributable to shareholders for 2022 was ¥97,871,370.77, a 2.52% increase compared to ¥95,468,878.12 in 2021[198]. - The net profit after deducting non-recurring gains and losses was ¥99,663,477.88, which is an 8.62% increase from ¥91,756,578.58 in the previous year[198]. - The basic earnings per share for 2022 was ¥0.3721, reflecting a 1.22% increase from ¥0.3676 in 2021[198]. - The cash flow from operating activities for 2022 was ¥189,461,778.48, a decrease of 14.87% compared to ¥222,552,216.23 in 2021[198]. - Quarterly operating revenue showed consistent growth, with Q4 2022 reaching ¥289,716,738.22, up from ¥209,134,132.83 in Q1 2022[199]. - The net profit attributable to shareholders in Q4 2022 was ¥37,108,764.11, significantly higher than ¥8,643,617.12 in Q1 2022[199]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 2 yuan per 10 shares, totaling 52.61 million, which aligns with its profit distribution policy[23]. - The company has not made any adjustments to its profit distribution policy during the reporting period, maintaining consistency with its established guidelines[22]. - The company plans to distribute a cash dividend of 2 RMB per 10 shares (including tax) to all shareholders, based on a total of 263,053,100 shares[187]. Corporate Governance and Compliance - The company has not reported any significant financial or non-financial reporting deficiencies during the reporting period[30]. - The company is committed to improving corporate governance and compliance with regulations to enhance its operational effectiveness and transparency[31]. - The company has implemented measures to strengthen internal control and auditing, focusing on monitoring significant financial transactions[52]. - The company has not faced any penalties or violations during the reporting period, indicating a stable operational environment[58]. - The company emphasizes the importance of considering the interests and demands of minority shareholders in decision-making processes[167]. - The company has maintained a stable and healthy development in its operations, driven by diligent and responsible board members[167]. Market Expansion and Product Development - The company aims to expand the clinical application of FibroScan in collaboration with major hospitals, targeting increased usage in primary healthcare institutions and departments beyond liver diseases[2]. - The company is focused on developing FibroScan as a key standard in the global NASH testing field, leveraging partnerships with international pharmaceutical companies[2]. - The company has established a global sales network covering over 100 countries, enhancing its market presence in Asia-Pacific, Europe, and North America[2]. - New product launches are expected to contribute an additional 300 million yuan in revenue over the next year[63]. - The company is investing in new technology development, allocating 100 million yuan for R&D initiatives[63]. - Market expansion plans include entering three new provinces, aiming for a 10% market share in these regions within two years[63]. - The company completed the acquisition of a smaller competitor, which is expected to enhance its market position and add 200 million yuan in annual revenue[63]. - The board has approved a new strategy focusing on digital transformation, with an investment of 50 million yuan planned for the next year[63]. Shareholder Structure and Remuneration - The company reported a total share count of 263,053,100, with 87.70% being unrestricted shares[141]. - The number of restricted shares decreased by 255,000, resulting in a total of 32,353,816 restricted shares, which is 12.30% of the total[141]. - The largest shareholder, Wang Guanyi, holds 22,315,603 restricted shares, which are subject to a 25% annual release[145]. - The company has a diversified shareholder structure with no single entity holding a majority stake[151]. - The total remuneration paid to directors, supervisors, and senior management in 2022 amounted to 6.3751 million yuan[161]. - Wang Guanyi, the chairman, received a pre-tax remuneration of 813,600 yuan[161]. - Lin Xin, the vice chairman and general manager, received a pre-tax remuneration of 1,010,600 yuan[161]. - The company’s board of directors and supervisors' remuneration is determined based on performance, ability, and position level[161]. - The company has implemented a performance evaluation system for senior management to determine their remuneration[161]. Social Responsibility and Environmental Initiatives - The company emphasizes environmental protection and sustainable development, continuously improving production processes and enhancing employee awareness of environmental protection[38]. - The company actively participates in social welfare initiatives, receiving the "2021 Public Welfare Collective Award" and providing 2 million fever-reducing medications to local government and medical units[39]. Financial Stability and Risk Management - The company has maintained a strong balance sheet, with total assets reported at 3 billion yuan and a debt-to-equity ratio of 0.5[63]. - There were no non-operating fund occupations by major shareholders during the reporting period, ensuring financial stability[71]. - The company reported a total investment of 18,780,000 in bank wealth management products, with an outstanding balance of 12,020,000[100]. - The company has no major guarantees during the reporting period[118]. - There were no significant asset or equity acquisitions or sales during the reporting period[95]. - The company maintained a good credit status with no significant debts due[109]. - The company did not experience any major penalties or rectification situations during the reporting period[108]. - The company has not engaged in any high-risk entrusted financial management during the reporting period[119]. - The company has no major contracts or leasing situations during the reporting period[121].

Financial Performance - The company achieved total operating revenue of 242 million yuan, an increase of 15.75% compared to the same period last year[23] - The net profit attributable to shareholders of the listed company was 13.0016 million yuan, representing a growth of 50.42% year-on-year[23] - The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 18.2514 million yuan, an increase of 107.88% compared to the previous year[23] - Total revenue for the quarter reached ¥242,063,684.65, an increase of approximately 15.7% compared to ¥209,134,132.83 in the previous period[27] - The company's operating revenue for the current period reached ¥242,063,684.65, representing a 15.75% increase compared to the same period last year[33] - Net profit attributable to shareholders was ¥13,001,623.68, marking a significant growth of 50.42% year-over-year[33] - The net profit after deducting non-recurring gains and losses increased by 107.88% to ¥18,251,415.69[33] - The net profit for the current period is CNY 36,074,251.24, compared to CNY 14,911,132.63 in the previous period, representing a growth of 141.5%[47] - The total comprehensive income for the current period is CNY 41,774,567.26, significantly higher than CNY 729,892.38 in the previous period[47] - The company reported a total profit of CNY 57,988,452.71, up from CNY 23,105,563.82, which is an increase of 150%[47] Cash Flow and Assets - The company received cash related to operating activities that increased by 1531%, mainly from external unit transactions[19] - The net cash flow from operating activities improved by 90.04%, totaling ¥70,573,746.91[33] - Cash flow from operating activities increased to CNY 70,573,746.91 from CNY 37,137,059.96, marking an increase of 90%[50] - Revenue from sales of goods and services received cash of CNY 294,299,249.39, up from CNY 231,787,697.08, indicating a growth of 27%[50] - Cash and cash equivalents increased to ¥535,049,843.40 from ¥479,210,709.13, reflecting a growth of approximately 11.7%[25] - The company's cash and cash equivalents increased by ¥55,839,134.27, with a closing balance of ¥535,049,843.40[32] - The cash inflow from investment activities totaled CNY 110,032,768.79, compared to CNY 329,896.60 in the previous period, showing a substantial increase[50] - The cash outflow from investment activities was CNY 121,835,582.49, resulting in a net cash flow from investment activities of CNY -11,802,813.70[50] Liabilities and Equity - The company's total liabilities increased to ¥734,350,448.95 from ¥696,935,426.18, representing a rise of approximately 5.4%[26] - The equity attributable to shareholders of the parent company reached ¥1,565,565,573.37, up from ¥1,545,394,966.62, indicating a growth of about 1.3%[27] Operational Metrics - Operating costs for the quarter were ¥185,573,350.49, slightly up from ¥185,038,994.01, indicating a marginal increase in operational expenses[27] - Research and development expenses amounted to ¥19,371,463.30, a decrease of about 6.9% from ¥20,806,658.60 in the previous period[27] - Inventory levels increased to ¥114,248,769.22 from ¥97,401,175.76, reflecting a rise of approximately 17.2%[25] - The total non-current assets increased to ¥1,318,821,743.47 from ¥1,292,300,817.82, showing a growth of about 2.1%[26] Other Financial Information - The company incurred share-based payment expenses of ¥4,064,000 due to the implementation of an employee stock ownership plan[42] - The weighted average return on net assets was 0.84%, an increase of 0.27% compared to the previous year[33] - The company reported a net cash outflow from financing activities of ¥2,714,178.14, an improvement from the previous year's outflow of ¥5,500,682.22[32] - The company has not disclosed any new product developments or market expansion strategies in the current report[23] - Other comprehensive income after tax for the current period is CNY 5,700,316.02, compared to a loss of CNY 14,181,240.25 in the previous period[47] - The company reported a net profit margin improvement, with net profit increasing to ¥55,733.16 from ¥415,610.41 in the previous period[27] - Non-operating income and expenses totaled -5,249,792.01 yuan, primarily due to public donations[5] - Contract liabilities increased by 121%, reflecting a rise in pre-received customer service orders[19] - Prepayments increased by 81%, driven by the procurement of Echosens equipment parts[19] - Other non-current assets rose by 137%, due to the new payment for land transfer fees[19] - The company reported a profit tax expense of CNY 21,914,201.47, compared to CNY 8,194,431.19 in the previous period, indicating an increase of 167%[47] - The company reported a net cash outflow from financing activities of ¥2,714,178.14, an improvement from the previous year's outflow of ¥5,500,682.22[32]

证券代码：300049 证券简称：福瑞股份 公告编号：2023-010 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 内蒙古福瑞医疗科技股份有限公司（以下简称"公司"）将于 2023 年 5 月 11 日(星期 四)15：00-17：00 在全景网举办 2022 年度业绩说明会。本次年度业绩说明会将采用网络 远程的方式举行，投资者可登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本 次年度业绩说明会。 出席本次说明会的人员有：公司副董事长、总经理林欣先生（代行财务总监职责）， 董事会秘书孙秀珍女士，独立董事耿方圆先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提前向投资 者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 10 日 15:00 前访问 http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面。公司将在 2022 年度业绩说明会上，对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与本次网上说明会。 （问题征集专题页面二维码） 特此公 ...

编号：2014-011 证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------------|------------------------|----------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ | 现场参观 □其他 （请文字说明其他活动内容） | | 参与单位名称及人员姓 | | 湘财证券 魏巍 国信证券 李少思 益民基金管理有限公司 | | 名 | 蒋俊国 蔡立平 | | | 时间 | 2014 年 7 月 1 | 日 上午 9:30 | | 地点 | 福瑞股份 会议室 | | | 上市公司接待人员姓名 | 董事会秘书 林欣 | | | 投资者关系活动 | | 问：林总，我们是资本市场长期投资者，第一次来到公司，希望 | | 主要内容介绍 | | 对公司有个更深 ...

证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 编号：2015- 012 | --- | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 编号：2015- 010 | --- | --- | --- | |----------------------------------|--------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 编号：2015- 007 | --- | --- | --- | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------------------------------------------------------------------------------|--------------------|----------------------------------------------------------------------------------------------------- ...

Financial Performance - The company achieved a profit of over 45 million in the first three quarters, with a non-deductible profit of over 47 million [2] - The majority of domestic profits are contributed by pharmaceuticals, particularly from the "Love Liver" management center [2] International Sales - In 2014, approximately 100 units of Fibroscan were sold in the U.S., with around 90 units sold in 2015 so far, indicating significant growth [2] - The Fibroscan device is currently sold directly in Western Europe and China, with plans to start direct sales in the U.S. next year [3] Product Pricing and Competition - The cost for a single Fibroscan test ranges from 120 to 180 yuan [3] - There are currently no competitors for Fibroscan in the global market [3] Fibroscan Model and Production - The main model sold is Fibroscan 502, with the older model 402 being less common in the market [3] - Fibroscan's lifespan is rated at 8 years, and calibration is required after 6 months or 2000 tests, costing approximately 30,000 yuan in China [4] Love Liver Management Center - There are over 90 "Love Liver" management centers, which are in the process of expanding profitability [4] - The center has over 40,000 online members and approximately 100,000 offline members [4] Drug Portfolio - The company represents over 80 types of drugs, primarily antiviral and liver protection medications [4] Future Strategies - The company is preparing to establish a medical device company in Shenzhen for the production, research, and sales of Fibroscan in China [3] - Future acquisitions will focus on liver disease diagnostics and treatments, with both domestic and international options being considered [5]